Welcome!

News Feed Item

Delivra Signs Exclusive Licensing Deal with Dosecann for Cannabis Oil Formulations in Metered Dose Formats

TORONTO, ON--(Marketwired - March 21, 2017) - Delivra Corp. (TSX VENTURE: DVA) ("Delivra" or the "Company"), Dosecann Inc. ("Dosecann") and ARA-Avanti Rx Analytics Inc. ("Avanti") announced today a strategic partnership to develop a unique suite of standardized products for the medical cannabis research, development, and commercialization markets.

"The Federal Government of Canada has numerous concerns, and barriers to overcome, before legalizing cannabis, including stricter regulatory controls. The partnership between the three companies addresses many of these concerns, providing greater safety and efficacy of medical cannabis specific products for the patient, with products that provide consistent, accurate dosing, and that are manufactured under pharmaceutical GMP Standards," said Dr. Joseph Gabriele, CEO of Delivra. "This collaboration between Delivra, Dosecann and Avanti addresses an exploding field of medicine by seeking to standardize, validate, package and distribute cannabis products in innovative mono-dose delivery platforms to licensed producers and other future legal distribution networks, ultimately meeting the needs of the patient."

"This agreement both validates Delivra's proprietary transdermal platform technology and allows Delivra to capitalize on an unmet need in the pain market: to provide quality, accuracy, consistency and repeatable dosing using cannabis-based therapeutics," added Dr. Joseph Gabriele. "This transaction provides our shareholders with compelling value to participate in the changing landscape of the cannabis marketplace in which standardization will be a key to success. With formulation and extraction beginning immediately, we expect that this transaction will be accretive to the Company's Q4 2017 revenue."

Strategic Rationale

Cannabis is a diversified plant that has many medicinal applications for diseases such as pain, sleep, anxiety, epilepsy, and cancer. However, cannabis is a controlled substance and needs to be accurately metered and dosed.

The collaboration supports and accelerates a standard in the medical cannabis market including:

  • Evidenced based science to validate its medicinal properties;
  • Expertise in formulation and transdermal delivery;
  • Cannabis standardization, ensuring each lot produced contains the exact amount of medicinal and non-medicinal ingredients;
  • Third-party regulatory testing to assure each product is safe and efficacious; and
  • A reliable dosing platform to prevent patients from overdosing and by receiving the same measured dose each time.

Properly administered, medical cannabis provides real alternatives to more addictive type drugs, including opioids.

Under the terms of the agreement, Delivra will use its expertise in formulation and proprietary delivery system platform to conduct preclinical and clinical studies for the evolving Canadian medical marijuana market along with international markets. Dosecann will potentially gain a suite of medical cannabis products for pain, sleep and anxiety packaged in a novel, revolutionary topical mono-dose format and a metered dosed oral spray. The costs of the clinical trials and research will be paid by Dosecann, Delivra will own the intellectual property, and Delivra will receive a royalty percentage on the related sales of the suite of medical cannabis products in a license agreement which continues for as long as the products are sold by Dosecann. Avanti will be responsible for the quality-control testing, extraction and production of the finished products under pharmaceutical GMP Standards.

"This three-way joint venture with Delivra and Avanti enables us to potentially formulate, manufacture and distribute medical cannabis products that are standardized, quality controlled and provided through unique delivery platforms effectively dosing medical cannabis," said Greg Boone, Founder of Dosecann.

ABOUT DELIVRA CORP.

Delivra Corp. is a specialty biotechnology company that has a proprietary transdermal delivery system platform that can shuttle pharmaceutical and natural molecules, through the skin, in a targeted specific manner. Delivra manufactures and sells a growing line of natural topical creams with the proprietary transdermal delivery system platform under the LivRelief™ brand, for conditions such as joint and muscle pain, nerve pain, varicose veins, wound healing, and under the LivSport™ brand for sports performance. LivRelief™ products are available in pharmacies, grocery chains, and independent health food stores across Canada, and on-line at www.livrelief.com. LivRelief™ pain and nerve pain products are also available in the United States on Amazon and at www.livrelief.com/us. In parallel with its consumer products business, Delivra also has a mandate to license its patent-pending proprietary transdermal delivery technology platform to pharmaceutical companies globally, for the transdermal delivery of repurposing Rx molecules to treat a broad range of conditions, along with licensing its over-the-counter products globally. Delivra is headquartered in Burlington, Ontario and has a research and development laboratory in Charlottetown, PEI.

Further information on Delivra can be found at www.delivracorp.com, www.livrelief.com for Canada and www.livrelief.com/us for the United States.

ABOUT ARA-AVANTI RX ANALYTICS INC.

ARA-Avanti Rx Analytics Inc. is the first Health Canada GMP and OCDS approved Contract Organization specializing in the field of controlled drugs and substances particularly in the area of Medicinal Marijuana, HEMP, Cannabinoids, and Marijuana based concentrated products. ARA-Avanti Rx Analytics Inc. offers a comprehensive menu of services ranging from analytical R&D and QC testing, large commercial scale extraction under a controlled environment, cannabinoids purification, cannabis infused-product formulation, and cannabis waste management by means of material denaturation, as well as the QA and regulatory consulting services. Our focus is in the provision of a broad range of sophisticated, state-of-the-art services to Health Canada approved licensed producers (LPs), authorized pharmacies, medical practitioners, Health Canada approved patients, government enforcement and regulatory agencies, and regulatory approved allied cannabis communities, and to continue to remain at the forefront of the healthcare industry, building an enviable reputation. ARA-Avanti Rx Analytics Inc. core values include: 1) Advance quality control and quality assurance for medical cannabis; 2) Support the safe consumption of medical cannabis; and 3) Ensure transparency for our medical cannabis community.

Further information on Avanti can be found at www.avantirx.com.

ABOUT DOSECANN INC.

Dosecann is a private specialty pharma company that has built a team of seasoned scientists, doctors and business leaders. We offer unique solutions to the emerging cannabis industry for numerous medical conditions. Dosecann fully understands the remarkable medical benefits of the natural Cannabis plant. We use evidence based, standardized formulations coupled with delivery platforms that will precisely dose cannabis extractions through Dosecann's RDR process (Refine, Define, Reproduce). Dosecann is presently formulating a monodose topical application to target specific areas of the body and an innovative metered dose oral spray formulation for patients that have chronic nerve pain, anxiety and sleeping disorders. With strategic partners, our goal is to validate our formulations through in vitro, pre-clinical, and clinical trials. We have proven expertise in taking pharmaceutical and natural products from concept to commercialization. All products are manufactured in a Health Canada GMP approved and OCS (Office of Controlled Substances) licensed organization. Initial products in development will meet Health Canada's regulatory requirements under the ACMPR program. Dosecann has built strategic relationships with key players in the industry to ensure constant innovation of new formulations and delivery technologies for numerous medical conditions. Our products will be distributed internationally to countries that allow for the importation of medial cannabis and related products. Dosecann will also distribute within Canada through the current LP model.

Further information on Dosecann can be found at www.dosecann.com.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This news release includes certain information and statements about management's view of future events, expectations, plans and prospects that constitute "forward-looking statements", which are not comprised of historical facts. Forward-looking statements may be identified by such terms as "believes", "anticipates", "intends", "expects", "estimates", "may", "could", "would", "will", or "plan", and similar expressions. Specifically, forward-looking statements in this news release include, without limitation, statements regarding: the research to be completed by Delivra for a suite of medical marijuana based products; the Company's drug research and development plans in general; the timing of operations; and estimates of market conditions. These statements involve known and unknown risks, uncertainties, and other factors that may cause actual results or events, performance, or achievements of Delivra to differ materially from those anticipated or implied in such forward-looking statements. The Company believes that the expectations reflected in these forward-looking statements are reasonable, but there can be no assurance that actual results will meet management's expectations. In formulating the forward-looking statements contained herein, management has assumed that business and economic conditions affecting Delivra will continue substantially in the ordinary course and will be favourable to Delivra, that clinical testing results will justify commercialization of the Company's drug candidates; that Delivra will be able to obtain all requisite regulatory approvals to commercialize its drug candidates, that such approvals will be received on a timely basis, and that Delivra will be able to find suitable partners for development and commercialization of its drug repurposing candidates on favourable terms. Although these assumptions were considered reasonable by management at the time of preparation, they may prove to be incorrect. Factors that may cause actual results to differ materially from those anticipated by these forward-looking statements include: unsuccessful outcomes in research for a suite of medical marijuana based products; uncertainties associated with obtaining regulatory approval to perform clinical trials and market products; the need to establish additional corporate collaborations, distribution or licensing arrangements; the ability of the Company to generate sales and profits; the Company's ability to raise additional capital if and when necessary; intellectual property disputes; increased competition from pharmaceutical and biotechnology companies; changes in equity markets, inflation, and changes in exchange rates; and other factors as described in detail in Delivra's public filings, all of which may be viewed on SEDAR (www.sedar.com). Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. Except as required by law, Delivra disclaims any intention and assumes no obligation to update or revise any forward-looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward-looking statements or otherwise.

Neither the TSX-V nor its Regulation Services Provider (as that term is defined in the policies of the TSX-V) accepts responsibility for the adequacy or accuracy of this release.

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest Stories
What sort of WebRTC based applications can we expect to see over the next year and beyond? One way to predict development trends is to see what sorts of applications startups are building. In his session at @ThingsExpo, Arin Sime, founder of WebRTC.ventures, will discuss the current and likely future trends in WebRTC application development based on real requests for custom applications from real customers, as well as other public sources of information,
SYS-CON Events announced today that SoftLayer, an IBM Company, has been named “Gold Sponsor” of SYS-CON's 18th Cloud Expo, which will take place on June 7-9, 2016, at the Javits Center in New York, New York. SoftLayer, an IBM Company, provides cloud infrastructure as a service from a growing number of data centers and network points of presence around the world. SoftLayer’s customers range from Web startups to global enterprises.
SYS-CON Events announced today that Ocean9will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Ocean9 provides cloud services for Backup, Disaster Recovery (DRaaS) and instant Innovation, and redefines enterprise infrastructure with its cloud native subscription offerings for mission critical SAP workloads.
Interoute has announced the integration of its Global Cloud Infrastructure platform with Rancher Labs’ container management platform, Rancher. This approach enables enterprises to accelerate their digital transformation and infrastructure investments. Matthew Finnie, Interoute CTO commented “Enterprises developing and building apps in the cloud and those on a path to Digital Transformation need Digital ICT Infrastructure that allows them to build, test and deploy faster than ever before. The int...
Have you ever noticed how some IT people seem to lead successful, rewarding, and satisfying lives and careers, while others struggle? IT author and speaker Don Crawley uncovered the five principles that successful IT people use to build satisfying lives and careers and he shares them in this fast-paced, thought-provoking webinar. You'll learn the importance of striking a balance with technical skills and people skills, challenge your pre-existing ideas about IT customer service, and gain new in...
SYS-CON Events announced today that Juniper Networks (NYSE: JNPR), an industry leader in automated, scalable and secure networks, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Juniper Networks challenges the status quo with products, solutions and services that transform the economics of networking. The company co-innovates with customers and partners to deliver automated, scalable and secure network...
In his session at @ThingsExpo, Eric Lachapelle, CEO of the Professional Evaluation and Certification Board (PECB), will provide an overview of various initiatives to certifiy the security of connected devices and future trends in ensuring public trust of IoT. Eric Lachapelle is the Chief Executive Officer of the Professional Evaluation and Certification Board (PECB), an international certification body. His role is to help companies and individuals to achieve professional, accredited and worldw...
VeriStor Systems has announced that CRN has named VeriStor to its 2017 Managed Service Provider (MSP) 500 list in the Elite 150 category. This annual list recognizes North American solution providers with cutting-edge approaches to delivering managed services. Their offerings help companies navigate the complex and ever-changing landscape of IT, improve operational efficiencies, and maximize their return on IT investments. In today’s fast-paced business environments, MSPs play an important role...
DevOps is often described as a combination of technology and culture. Without both, DevOps isn't complete. However, applying the culture to outdated technology is a recipe for disaster; as response times grow and connections between teams are delayed by technology, the culture will die. A Nutanix Enterprise Cloud has many benefits that provide the needed base for a true DevOps paradigm. In his Day 3 Keynote at 20th Cloud Expo, Chris Brown, a Solutions Marketing Manager at Nutanix, will explore t...
What if you could build a web application that could support true web-scale traffic without having to ever provision or manage a single server? Sounds magical, and it is! In his session at 20th Cloud Expo, Chris Munns, Senior Developer Advocate for Serverless Applications at Amazon Web Services, will show how to build a serverless website that scales automatically using services like AWS Lambda, Amazon API Gateway, and Amazon S3. We will review several frameworks that can help you build serverle...
SYS-CON Events announced today that Linux Academy, the foremost online Linux and cloud training platform and community, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Linux Academy was founded on the belief that providing high-quality, in-depth training should be available at an affordable price. Industry leaders in quality training, provided services, and student certification passes, its goal is to c...
SYS-CON Events announced today that Interoute, owner-operator of one of Europe's largest networks and a global cloud services platform, has been named “Bronze Sponsor” of SYS-CON's 20th Cloud Expo, which will take place on June 6-8, 2017 at the Javits Center in New York, New York. Interoute is the owner-operator of one of Europe's largest networks and a global cloud services platform which encompasses 12 data centers, 14 virtual data centers and 31 colocation centers, with connections to 195 add...
SYS-CON Events announced today that Telecom Reseller has been named “Media Sponsor” of SYS-CON's 20th International Cloud Expo, which will take place on June 6–8, 2017, at the Javits Center in New York City, NY. Telecom Reseller reports on Unified Communications, UCaaS, BPaaS for enterprise and SMBs. They report extensively on both customer premises based solutions such as IP-PBX as well as cloud based and hosted platforms.
FinTech is the sum of financial and technology, and it’s one of the fastest growing tech industries. Total global investments in FinTech almost reached $50 billion last year, but there is still a great deal of confusion over what it is and what it means – especially as it applies to retirement. Building financial startups is not simple, but with the right team, technology and an innovative approach it can be an extremely interesting domain to disrupt. FinTech heralds a financial revolution that...
SYS-CON Events announced today that Loom Systems will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Founded in 2015, Loom Systems delivers an advanced AI solution to predict and prevent problems in the digital business. Loom stands alone in the industry as an AI analysis platform requiring no prior math knowledge from operators, leveraging the existing staff to succeed in the digital era. With offices in S...